PM
VKTX icon

Prosight Management’s Viking Therapeutics VKTX Stock Holding History

Prosight Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,000
Closed -$1.46M – 48
2026
Q1 		$1.46M Buy
+45,000
New +$1.45M 0.24% 39
2024
Q4 		– Sell
-48,000
Closed -$3.04M – 50
2024
Q3 		$3.04M Sell
48,000
-67,000
-58% -$3.93M 0.75% 32
2024
Q2 		$6.1M Buy
115,000
+75,954
+195% +$4.98M 1.82% 19
2024
Q1 		$3.2M Buy
+39,046
New +$1.74M 0.89% 29
2019
Q1 		– Sell
-624,000
Closed -$4.77M – 44
2018
Q4 		$4.77M Buy
624,000
+349,590
+127% +$4.18M 2.46% 16
2018
Q3 		$4.78M Buy
+274,410
New +$3.27M 2.67% 15

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Prosight Management's VKTX Position: Q2 2026 in Review

Prosight Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 45,000 shares — an estimated $1.46M sold.

Prosight Management first reported a position in VKTX in Q3 2018 and held it in 6 quarters. The position peaked at $6.1M in Q2 2024. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Prosight Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prosight Management sold 45,000 Viking Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Prosight Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 6 quarters.
  • Prosight Management's Viking Therapeutics position peaked at $6.1M in Q2 2024.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.